Butterfly Network, Inc.

AI-generated fair value estimate for this company.

Method: 10-year phased revenue/FCF DCF: revenue grows from $112.1M (TTM) at a 20% CAGR to $279.2M by year 5 as point-of-care ultrasound adoption scales, then a 10% CAGR to $449.7M by year 10; FCF margin phases in from -20% (year 1) to a mature 15% (years 6-10); 13% discount rate; 3% terminal growth; $105.56M net cash added; 266.29M shares outstanding.

Reasoning: Butterfly Network is a growth-stage medical device company still burning cash while it scales adoption of its handheld ultrasound platform, so a phased revenue-ramp/margin-normalization DCF with a 13% discount rate for commercialization and competitive risk is more appropriate than extrapolating current negative FCF; its meaningful net cash cushion is added back.